Arrhythmias & electrophysiology

The left atrial appendage exclusion for prophylactic stroke reduction (LEAAPS) trial: Rationale and design

Am Heart JPublished Randomised controlled trial

Study context

Population
Adults ≥18 years undergoing planned cardiac surgery, without pre-existing atrial fibrillation (AF) but at increased risk of AF and stroke (age, CHA2DS2-VASc score, left atrium size or brain natriuretic peptide)planned enrolment
Participants
6,500 adults
Planned comparison
Left atrial appendage exclusion (LAAE) with AtriClip vs no LAAE during cardiac surgery
Primary endpoint
First occurrence of ischemic stroke, systemic arterial embolism, or surgical or endovascular LAA closure
Methodological detailsrationale and design, international, prospective, multicentre, blinded, 1:1 randomisation, 250 sites, Follow-up every 6 months for a minimum of 5 years, Patient and healthcare providers outside the operating room blinded to allocation, Powered secondary endpoint: ischemic stroke or systemic arterial embolism, Primary safety endpoint (through 30 days): pericardial effusion requiring percutaneous or surgical treatment, peri-operative major bleeding, deep sternal wound infection, or MI, Primary analysis when 469 patients have had an ischemic stroke or systemic embolism
  • Rationale and design
  • International
  • Prospective
  • Multicentre
  • Blinded
  • 1:1 randomisation
  • 250 sites
  • Follow-up every 6 months for a minimum of 5 years
  • Patient and healthcare providers outside the operating room blinded to allocation
  • Powered secondary endpoint: ischemic stroke or systemic arterial embolism
  • Primary safety endpoint (through 30 days): pericardial effusion requiring percutaneous or surgical treatment, peri-operative major bleeding, deep sternal wound infection, or MI
  • Primary analysis when 469 patients have had an ischemic stroke or systemic embolism

No results yet. This paper sets out the design of a trial; its results are to come.

Original publication

The left atrial appendage exclusion for prophylactic stroke reduction (LEAAPS) trial: Rationale and design. Am Heart J. Published 11 October 2024. doi:10.1016/j.ahj.2024.10.006

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.